102 related articles for article (PubMed ID: 11090789)
1. Inhibition of platelet aggregability by losartan in essential hypertension.
Levy PJ; Yunis C; Owen J; Brosnihan KB; Smith R; Ferrario CM
Am J Cardiol; 2000 Dec; 86(11):1188-92. PubMed ID: 11090789
[TBL] [Abstract][Full Text] [Related]
2. Antithrombotic effects of losartan in patients with hypertension complicated by atrial fibrillation: 4A (Angiotensin II Antagonist of platelet Aggregation in patients with Atrial fibrillation), a pilot study.
Sakamoto T; Kudoh T; Sakamoto K; Matsui K; Ogawa H
Hypertens Res; 2014 Jun; 37(6):513-8. PubMed ID: 24572913
[TBL] [Abstract][Full Text] [Related]
3. Effect of antihypertensive therapy using enalapril or losartan on haemostatic markers in essential hypertension: a pilot prospective randomised double-blind parallel group trial.
Li-Saw-Hee FL; Beevers DG; Lip GY
Int J Cardiol; 2001 May; 78(3):241-6. PubMed ID: 11376827
[TBL] [Abstract][Full Text] [Related]
4. In vivo effect of losartan on platelet aggregation in patients with hypertension.
Akdemir R; Ozhan H; Yazici M; Gunduz H; Duran S; Gurel C; Ozdas S; Uyan C; Basar I; Ulutin T
Heart Vessels; 2004 Jul; 19(4):167-71. PubMed ID: 15278389
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of ACE-inhibition and angiotensin II antagonism on fibrinolysis and insulin sensitivity in hypertensive postmenopausal women.
Fogari R; Zoppi A; Preti P; Fogari E; Malamani G; Mugellini A
Am J Hypertens; 2001 Sep; 14(9 Pt 1):921-6. PubMed ID: 11587159
[TBL] [Abstract][Full Text] [Related]
6. Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension.
Erdem Y; Usalan C; Haznedaroğlu IC; Altun B; Arici M; Yasavul U; Turgan C; Cağlar S
Am J Hypertens; 1999 Nov; 12(11 Pt 1):1071-6. PubMed ID: 10604482
[TBL] [Abstract][Full Text] [Related]
7. Platelet aggregability in patients with hypertension treated with angiotensin II type 1 receptor blockers.
Sato Y; Fujii S; Imagawa S; Ohmura K; Ohmura Y; Andoh Y; Dong J; Ishimori N; Furumoto T; Tsutsui H
J Atheroscler Thromb; 2007 Feb; 14(1):31-5. PubMed ID: 17332690
[TBL] [Abstract][Full Text] [Related]
8. Effects of losartan on fibrinolytic parameters and von Willebrand factor in Chinese subjects with hypertension: a comparative study versus atenolol.
Liu J; Sun NL; Yang J; Huang JH
J Int Med Res; 2009; 37(3):595-600. PubMed ID: 19589241
[TBL] [Abstract][Full Text] [Related]
9. The impact of angiotensin II receptor blockade and the DASH diet on markers of endogenous fibrinolysis.
Erlinger TP; Conlin PR; Macko RF; Bohannon AD; Miller ER; Moore TJ; Svetkey LP; Appel LJ
J Hum Hypertens; 2002 Jun; 16(6):391-7. PubMed ID: 12037693
[TBL] [Abstract][Full Text] [Related]
10. Effects of atenolol or losartan on fibrinolysis and von Willebrand factor in hypertensive patients with left ventricular hypertrophy.
Boman K; Boman JH; Andersson J; Olofsson M; Dahlöf B
Clin Appl Thromb Hemost; 2010 Apr; 16(2):146-52. PubMed ID: 19825910
[TBL] [Abstract][Full Text] [Related]
11. [Effect of asymmetric dimethylarginine on platelet-aggregation and losartan intervention in spontaneous hypertensive rat models].
Xia K; Li D; Zhao ZY; Yang TL
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Oct; 31(5):645-9, 654. PubMed ID: 17062922
[TBL] [Abstract][Full Text] [Related]
12. Effects of losartan versus hydrochlorothiazide on indices of endothelial damage/dysfunction, angiogenesis and tissue factor in essential hypertension.
Chung NA; Beevers DG; Lip G
Blood Press; 2004; 13(3):183-9. PubMed ID: 15223728
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the renin-angiotensin system does not reduce platelet activity at rest or during stress in hypertension.
Schwieler JH; Kahan T; Wallén NH; Nussberger J; Hjemdahl P
J Hypertens; 2013 Aug; 31(8):1676-82. PubMed ID: 23625113
[TBL] [Abstract][Full Text] [Related]
14. Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients.
Fogari R; Mugellini A; Zoppi A; Corradi L; Preti P; Lazzari P; Derosa G
Am J Hypertens; 2002 Apr; 15(4 Pt 1):316-20. PubMed ID: 11991216
[TBL] [Abstract][Full Text] [Related]
15. Eprosartan effect on fibrinolytic/hemostatic variables in arterial hypertension: a comparative study to losartan.
Makris TK; Stavroulakis G; Papadopoulos DP; Krespi P; Hatzizacharias A; Zilidis A; Tsoukala C; Votteas VE
Drugs Exp Clin Res; 2004; 30(3):125-32. PubMed ID: 15366789
[TBL] [Abstract][Full Text] [Related]
16. Effect of aspirin on blood pressure in hypertensive patients taking enalapril or losartan.
Nawarskas JJ; Townsend RR; Cirigliano MD; Spinler SA
Am J Hypertens; 1999 Aug; 12(8 Pt 1):784-9. PubMed ID: 10480471
[TBL] [Abstract][Full Text] [Related]
17. Effects of losartan, an angiotensin II receptor antagonist, on the fibrinolytic system in hypertensive patients.
Saito M; Kawasaki S; Hashiba T; Chen CJ; Hatakeyama H; Asakura H; Kikuchi M; Matsuda T
Int J Hematol; 1999 Jul; 70(1):60-1. PubMed ID: 10446499
[No Abstract] [Full Text] [Related]
18. Effects of AT1 receptor antagonist losartan on sICAM-1 and TNF-alpha levels in uncomplicated hypertensive patients.
Sardo MA; Castaldo M; Cinquegrani M; Bonaiuto M; Fontana L; Campo S; Campo GM; Altavilla D; Saitta A
Angiology; 2004; 55(2):195-203. PubMed ID: 15026875
[TBL] [Abstract][Full Text] [Related]
19. Effects of isradipine sustained release on platelet function and fibrinolysis in essential hypertensives with or without other risk factors.
Ranieri G; Filitti V; Andriani A; Bonfantino MV; Lamontanara G; Cavallo A; Milani M; De Cesaris R
Cardiovasc Drugs Ther; 1996 May; 10(2):119-23. PubMed ID: 8842503
[TBL] [Abstract][Full Text] [Related]
20. Different effects of losartan and delapril on plasma PAI-1 levels in patients with mild to moderate hypertension.
Paterna S; Di Garbo V; Avellone G; Di Pasquale P; Tuttolomondo A; Follone G; Cardinale A; Maniscalchi T; Licata G
Int J Cardiol; 2003 Dec; 92(2-3):303-4. PubMed ID: 14659871
[No Abstract] [Full Text] [Related]
[Next] [New Search]
